The vitamin D receptor (VDR) is an endocrine nuclear receptor that binds with high affinity its natural ligand 1␣,25-dihydroxyvitamin D 3 . Gemini is a 1␣,25-dihydroxyvitamin D 3 analog with two identical side chains that, despite its significantly increased volume, binds to the VDR and can function as a potent agonist. This study demonstrates that, at excess corepressor (CoR) levels, Gemini shifts from an agonist to an inverse agonist that actively recruits CoR proteins to the VDR and mediates superrepression. Under these conditions Gemini stabilizes the VDR into a silent conformation, in which helix 12 of the ligand-binding domain is repositioned and thus unable to contribute to coactivator interaction. Amino acid F422 has been described as the lock of helix 12 and seems to be the most critical VDR residue in the inverse agonistic action of Gemini. Molecular dynamics simulations of the Gemini-VDR complex support these observation by indicating that the second side chain of Gemini induces tension to the receptor structure that can be released by a shift of helix 12. Taken together, Gemini is the first described (conditional) inverse agonist to an endocrine nuclear receptor and may function as a sensor for the cell-specific coactivator/CoR ratio. (Molecular Endocrinology 17:
plays an important role in calcium resorption and bone formation (2) and was also shown to act as a regulator of cellular proliferation, differentiation, and apoptosis (3) . Like all NRs, VDR has a highly conserved DNAbinding domain and a less conserved ligand-binding domain (LBD). The LBD is formed by 12 ␣-helices, and its overall architecture is similar for all NRs (4). VDR acts preferentially as a heterodimer with the retinoid X receptor (RXR) on specific DNA sequences in promoter regions of 1␣,25(OH) 2 D 3 target genes, referred to as 1␣,25(OH) 2 D 3 response elements (VDREs) (5) . The VDR-RXR-VDRE complex is the core of DNAdependent 1␣,25(OH) 2 D 3 signaling (6) , and the stabilization of the agonistic conformation of the LBD of the VDR via the repositioning of the most carboxy-terminal ␣-helix (helix 12) is the crucial step in this signaling process. In detail, this is achieved by a hydrogen bond between the C25-hydroxyl group of 1␣,25(OH) 2 D 3 and H397 of the receptor (7) and is supported by an additional, less important, hydrogen bond with H305 (8) . In the presence of agonist, H397 is able to form van der Waals contacts with F422 of helix 12. This keeps helix 12 in a position that is optimal for the charge clamp between E420 (helix 12) and K246 (helix 3), which allows the LXXLL NR interaction domain of coactivator (CoA) proteins into a hydrophobic cleft on the surface of the LBD (9) . CoA proteins, in turn, contact and recruit other components of the basal transcriptional machinery, the result of which is enhanced transcription of 1␣,25(OH) 2 D 3 target genes (10) .
Nearly all NRs are known to interact with CoA proteins, but it is unclear, whether all form complexes with corepressor (CoR) proteins, such as NR corepressor (NCoR), Alien, and others (11) . Classical CoRs act as a specific bridge between transcription factors and histone deacetylases (HDACs), which are enzymes that locally close chromatin (12) . It is thought that NRs interact with CoRs only in the absence of ligand, i.e. in their apo-form. Agonistic ligand binding to the LBD of the VDR initiates the dissociation of CoRs. VDR has been shown to interact with the CoR proteins NCoR, Alien, and Pit-1 (13, 14) . This provides VDR with intrinsic repressing activity in the absence of ligand. It is thought that nonliganded VDR-RXR heterodimers actively repress 1␣,25(OH) 2 D 3 target genes by binding to their respective VDREs.
Abbreviations: ANF, Atrial natriuretic factor; CAR, constitutive androstane receptor; CoA, coactivator; CoR, corepressor; DMSO, dimethylsulfoxide; GST, glutathione S-transferase; HDAC, histone deacetylase; LBD, ligand-binding domain; MD, molecular dynamics; NCoR, nuclear receptor corepressor; NR, nuclear receptor; 1␣,25(OH) 2 Humans have 37 orphan NR superfamily members and, for some of them in past years, low-affinity ligands have been identified (K d value of 1 M or higher) (15) . One of these adopted orphan NRs is the constitutive androstane receptor (CAR), which is an unusual member of the family, because it interacts in the absence of ligand with CoAs and displays constitutive activity (16) . Furthermore, the natural CAR ligand androstanol acts as an inverse agonist by decreasing CoA interaction (17) and increasing CAR-CoR complex formation (13) . This opens the question of whether inverse agonists exist only for constitutively active NRs or whether inverse agonists can be developed for other ligand-activated members of the NR superfamily, such as VDR.
More than 2000 analogs of 1␣,25(OH) 2 D 3 have been synthesized in an effort to improve the potency and specificity of the physiological effects of vitamin D (18) . The large majority of these analogs have been modified at their side chain, which in most cases increases their metabolic stability and the half-life of the VDR-ligand complex (19, 20) . Superagonists carry only minor modifications compared with the natural hormone and stabilize the same agonistic VDR conformation via the H397-F422 interaction (21) . An exception is Gemini, which is the first 1␣,25(OH) 2 D 3 analog that carries two side chains (22, 23) . This analog has approximately 25% higher volume than the natural hormone. Gemini was shown to act as a potent agonist, and in the presence of CoAs, RXR, and DNA the ligand is able to bind the VDR in its agonistic (active) conformation (22, 24) . Molecular dynamics (MD) simulations of the Gemini-VDR complex demonstrated that one of the two side chains of Gemini has the same location as in the natural hormone, whereas for the second side chain two approximately equal positions were identified (25) . Receptor mutagenesis, CoA interaction studies in vitro, and functional assays in living cells confirmed that Gemini uses both possible positions. However, Gemini has also been shown to stabilize a silent (nonagonistic) conformation of the VDR, in which the receptor favors CoR interaction to complex formation with CoAs (24, 26) . This study attempts to answer the question, whether Gemini can also act as an inverse agonist to the VDR. In functional assays it could be demonstrated that CoR excess shifts Gemini from an agonist to an inverse agonist. Amino acid F422 was shown to have a critical role in this process as confirmed by in vitro interaction studies with NCoR and conformational analysis by limited protease digestion. MD simulations indicated that the second side chain of Gemini creates tension within the LBD of VDR, which in excess of CoR proteins can be released by shifting helix 12 into an inverse agonistic position. Gemini therefore seems to be a conditional inverse agonist of the VDR.
RESULTS AND DISCUSSION
The VDRE of the human osteocalcin gene promoter is composed of three NR binding sites forming direct repeats of six and three spacing nucleotides (27) . In addition, it is overlaid by a binding site for the transcription factor AP-1 (28) (see Fig. 1 for sequence and schematic structure). Binding of AP-1 provides the VDRE with a basal activity in the MCF-7 human breast cancer model cell line that is significantly higher than that of other known VDREs (29) . Therefore, this VDRE is suited for monitoring studies in which both activating and repressing activities of the VDR could be measured (14) . Treatment with the HDAC inhibitor trichostatin A (TSA) allows monitoring the derepressed state of the VDRE, i.e. its basal activity at maximally deacetylated chromatin.
In this study, reporter gene assays were performed from extracts of MCF-7 cells being transiently transfected with a luciferase reporter gene construct under the control of one copy of the human osteocalcin VDRE fused with the thymidine kinase (tk) promoter (Fig. 1, A-C) . The activity level of the derepressed state of the VDRE appeared to be independent from overexpression of VDR, RXR, or NCoR in the cells and therefore served as an internal reference (compare lanes 2, 5, 8, 11, 14, 17, 20 , and 23 in Fig. 1A and lanes 2 and 4 in Fig. 1C ). The first series of assays (Fig. 1A 22 and 10) . In summary, these data indicate that there is minor repression of the model VDRE via endogenously expressed VDR that can be increased by overexpression of VDR wt . In contrast, RXR wt alone has no repressive effects but blocks the repression by endogenous and overexpressed VDR. Interestingly, NCoR induces superrepression only when VDR exceeds the amount of RXR.
In the next series of reporter gene assays (Fig. 1B ) the impact of helix 12 of both RXR and VDR on the , and again reversed Gemini from a (weak) agonist to an inverse agonist (1.6-fold reduction, lane 24). Taken together, at standard conditions Gemini was at least as potent a VDR agonist as 1␣,25(OH) 2 D 3 , but in excess of CoR it has a clearly reduced agonistic potential. Confirming previous reports (30, 31) , helix 12 of VDR proved to be essential for the agonistic action of the natural hormone. For the agonism of Gemini, helix 12 is also important but not as critical as for that of 1␣,25(OH) 2 D 3 . Remarkably, the lack of VDR's helix 12 combined with a CoR excess allows one to detect the shift of Gemini from agonism to an inverse agonism. In contrast, helix 12 of RXR appears to inhibit the repression potential of VDR and explains why the overexpression of RXR wt increased the basal activity of the model VDRE (see Fig. 1A ). Similar observations were already reported for other NRs, such as the retinoid acid receptor (32) and the thyroid hormone receptor (33) . As compared with these reports it can be assumed that helix 12 of RXR reduces the interaction potential of VDR-RXR heterodimers with NCoR.
Earlier reports on VDR (30, 31) and comparisons with other members of the NR superfamily, such as CAR (17), have indicated that two amino acid of helix 12 are most critical for the agonist action on the NR. The first is the highly conserved glutamate residue (E420 in VDR) that is part of the charge clamp for CoA interaction. The second is a hydrophobic amino acid, which is found in most NRs as the second carboxyterminal amino acid to the glutamate (F422 in VDR). This hydrophobic amino acid serves as a ligand-triggered lock of helix 12 and stabilizes the helix in a position that is optimal for the charge clampcontrolled CoA interaction (see also Fig. 4A ). The reporter gene assays in Fig. 1C assessed the contribution of these two amino acids to the different functional profiles of 1␣,25(OH) 2 D 3 and Gemini. The basal activities mediated by VDR wt -RXR wt and VDR ⌬H12 -RXR wt heterodimers (lanes 1 and 3) were found to be nearly identical and approximately 2-fold repressed in reference to the derepressed state of the VDRE (lanes 2 and 4). The functional profile of VDR ⌬H12 -RXR wt heterodimers was found to be identical to that described in the previous experimental series (compare lanes 3 and 5-9 in Fig. 1C with lanes 13-18 in Fig. 1B) . The shift of Gemini from agonist to inverse agonist could not be observed with VDR E420A -RXR wt heterodimers (compare lanes 12 and 15). Moreover, the overexpression of NCoR had no significant effect (compare lanes 10-12 with lanes 13-15). In contrast, the functional profile of VDR F422A -RXR wt heterodimers (lanes [16] [17] [18] [19] [20] [21] was identical to that of VDR ⌬H12 -RXR wt heterodimers (lanes 3 and 5-9). This indicates that the amino acid F422 is critical for the helix 12-dependent profile of Gemini, i.e. its ability to shift from agonist to inverse agonist.
NCoR is known to inhibit in combination with HDAC3 the Jun kinase pathway (34) , so that the AP-1 site overlaying the osteocalcin VDRE (Fig. 1A) may contribute to the effects observed in Fig. 1 , B and C. We therefore performed reporter gene assays on four copies of the DR3-type VDRE of the rat atrial natriuretic factor (ANF) gene, which does not contain an overlaid AP-1 site (Fig. 1D) . When using VDR wt , TSA activated this VDRE multimer by a factor of 4.3 (lane 2), which is rather low compared with approximately 40-fold stimulation by 1␣,25(OH) 2 D 3 and Gemini (lanes 3 and 5). TSA and the two VDR ligands showed no synergistic or additive effects (lanes 4 and 6). The of the DR3-type VDRE of the rat ANF gene promoter (D) and the indicated expression vectors for wild-type or mutant VDR and RXR and full-length NCoR proteins. The cells were treated for 16 h with ethanol (0.1%), TSA, 1␣,25(OH) 2 D 3 , or Gemini (each 100 nM). Relative luciferase activity was calculated in comparison to solvent-induced controls and normalized to the basal activity of VDR wt -RXR wt heterodimers. Columns represent the mean of at least three experiments and the tips of the bars indicate SD. Statistical analysis was performed by two-tailed, paired Student's t test, and P values were calculated in reference to basal activity of VDR wt -RXR wt heterodimers (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001).
overexpression of NCoR caused a slight reduction of basal activity (lane 7) and of inducibility with 1␣,25(OH) 2 D 3 (32.1-fold, lane 9). Comparable with the observation of the osteocalcin VDRE (Fig. 1B, lane 6) , stimulation with Gemini was significantly reduced in the presence of NCoR (lane 11). Interestingly, this reduction was reversed by a costimulation with TSA (lane 12). This could be explained by the assumption that some VDR molecules are stabilized by Gemini in a conformation that recruits NCoR and mediates repression via HDACs, whereas the remaining VDR subpopulation is responsible for the reduced activation. TSA inhibits the Gemini-induced repression and full activity is restored. When using VDR F422A , the stimulation by 1␣, 25 18) . In confirmation of the effects that were observed on the osteocalcin VDRE (Fig. 1C,  lane 21) , the overexpression of NCoR turned Gemini from a weak agonist (lane 17) to an inverse agonist (lane 23). This inverse agonistic effect was partially reversed by cotreatment with TSA (lane 24). In conclusion, on both VDRE types the same effects were observed. Therefore, the possibility of a contribution of AP-1 to the inverse agonistic action of Gemini is unlikely. TSA is able to reverse the conditional inverse agonism of Gemini, which suggests that HDACs are involved in this phenomenon.
Next we used glutathione S-transferase (GST)-pulldown assays to compare the ligand-triggered interaction of NCoR with VDR wt and its mutants in solution ( Fig. 2A) . GST-NCoR 1649Ϫ2453 precipitated similar amounts of VDR wt , VDR ⌬H12 , VDR E420A , and VDR F422A input (ϳ10%, compare lanes 1, 4, 7, and 10). VDR wt and VDR E420A showed a nearly identical profile, which is characterized by an equal reduction of NCoR-VDR interaction after the addition of 1␣,25(OH) 2 D 3 or Gemini (compare lanes 2, 3, 8, and 9 ). This supports earlier reports on 1␣,25(OH) 2 D 3 -triggered dissociation of NCoR-VDR complexes (13, 14) . Interestingly, VDR ⌬H12 and VDR F422A formed another pair of identical NCoR interaction profiles (compare lanes 4-6 with lanes 10-12). However, in this case Gemini significantly increased the VDR-NCoR complex formation (lanes 6 and 12) but 1␣,25(OH) 2 D 3 showed no effect (lanes 5 and 11). To support the results from this in vitro assay a similarly designed mammalian two-hybrid assay was performed in MCF-7 cells (Fig. 2B) . In this assay the effect of expressing a VP16-NCoR 1552Ϫ2453 fusion protein on the solvent, 1␣,25(OH) 2 D 3 -and Geminitriggered activity of wild-type and mutant versions of GAL4 DBD -VDR LBD was assessed. This cell-based assay provided essentially the same results as the GSTpull-down assay. VDR wt and VDR E420A form a pair with a similar profile, in which in the absence of ligand a protein-protein interaction between the VDR-LBD and NCoR is observed (lanes 4 and 10) that is abolished after ligand treatment (lanes 5, 6, 11, and 12). VDR ⌬H12 and VDR F422A also showed a similar profile, in which Gemini (lanes 9 and 12), but not 1␣,25(OH) 2 D 3 (lanes 8 and 11), significantly increased the interaction between VDR and NCoR. Taken together, both types of protein-protein interaction assays support the result of the functional assays (Fig. 1C) indicating that F422 , but not E420, is the critical amino acid for a Geminitriggered interaction between VDR and NCoR.
Limited protease digestion allowed us to monitor the functional conformations of NRs (6) . VDR agonists are known to stabilize the VDR in the active conformation c1 (30) , in which the receptor is able to interact with CoA proteins. The VDR LBD was crystallized in this conformation (7), which is characterized by helix 12 in the lid-closed position as schematically depicted in Fig. 3 . In contrast, in the silent conformation c3 (24) E420A , and VDR F422A , limited protease digestion assays were performed with the receptor alone. VDR-RXR heterodimers bound to DNA and VDR-RXR heterodimers on DNA in the presence of NCoR (Fig. 3) . Under the experimental conditions of these assays the solvent dimethylsulfoxide (DMSO) stabilized only 5% or less (lanes 2, 5, 8, 12, 15, 18, 22, 25, 28, 32, 35, and 38) of receptor input (lanes 1, 11, 21, and 31) in approximately equal proportions of c1 and c3. Consistent with results of the functional and interaction assays (Figs. 1C and 2), VDR wt and VDR E420A displayed a similar profile. This is characterized by preferential stabilization of the LBD in c1, when the natural ligand was applied (lanes 3, 6, 9, 23, 26, and 29), and in c3, when Gemini was used (lanes 4, 10, 24, and 30). In the presence of RXR and DNA, but in the absence of NCoR, Gemini stabilized the receptor to approximately equal amounts in c1 and c3 (lanes 7 and 27). With VDR in solution, the profiles of VDR ⌬H12 and VDR F422A resembled each other, i.e. both 1␣,25(OH) 2 D 3 and Gemini stabilized the LBD in c3 (lanes 13, 14, 33, and 34). A similar profile was observed with VDR F422A in the presence of RXR and DNA (lanes 36 and 37), whereas under the same conditions with VDR ⌬H12 relatively low amounts of the LBD were stabilized to a slightly higher extent in c1 than in c3 (lanes 16 and 17) . However, the most prominent difference between VDR ⌬H12 and VDR F422A 
. Ligand-Triggered VDR-NCoR Interaction
A, GST-pull down assays were performed with bacterially expressed GST-NCoR 1649Ϫ2453 and full-length in vitro translated, 35 S-labeled wild-type or mutant VDR in the presence of DMSO (as solvent control), 1␣,25(OH) 2 D 3 , or Gemini (each 1 M). After precipitation and washing the samples were electrophoresed through 10% SDS-polyacrylamide gels, and the percentage of precipitated VDR proteins with respect to input was quantified using a Fuji FLA3000 reader. Representative gels are shown. B, Mammalian two-hybrid assays were performed in MCF-7 cells that were transiently transfected with a reporter gene construct driven by three copies of the GAL4 binding site and the expression vector for GAL4 DBD (as a control) or GAL4 DBD VDR LBD fusion protein (wild type or mutant) in the presence or absence of the expression vector for VP16-NCoR 1552Ϫ2453 . The cells were treated for 16 h with ethanol (0.1%), 1␣,25(OH) 2 D 3 , or Gemini (each 100 nM). The stimulation of luciferase activities due to the overexpression of VP16-NCoR 1552Ϫ2453 was calculated. Columns represent the mean of at least three experiments, and the tips of the bars indicate the SD values. Statistical analysis was performed by two-tailed, paired Student's t test, and P values were calculated in reference to NCoR interaction in the presence of solvent (*, P Ͻ 0.05; **, P Ͻ 0.01).
verse agonist to an agonist, which can be specifically blocked by mutating F422. Interestingly, in the presence of NCoR, Gemini shifts back to an inverse agonist, which explains the observations of the functional assays (Fig. 1C) . Moreover, the limited protease digestion assay appears to be more sensitive than the reporter gene assay (Fig. 1) and the GST-pull down assay (Fig. 2) , because it monitors the conversion of Gemini from agonist to inverse agonist and vice versa already with VDR wt and not only with VDR F422A .
As a preparation for MD simulations, Gemini was docked into the crystal structure of the VDR-LBD (7), which has been completed by molecular modeling with the amino acid residues 118, 119, 375-377, and 424-427. The conformational analysis of Gemini showed that the first side chain keeps the same position as the single side chain of 1␣,25(OH) 2 (25) (see the whole VDR-LBD view in Fig. 4A) . In position 1 the extra side chain of Gemini (blue in Fig. 4A ) points in the same direction as the methyl-group (C21) at C20 of the 1␣,25(OH) 2 D 3 -VDR-LBD crystal structure (7), whereas in position 2 (green) the second side chain is rotated by 120°in relation to its location in position 1. Ligand-triggered conformational changes of the VDR-LBD, as observed by limited protease digestion (Fig. 3) , can be reflected on a structural level by a change of the distance of critical amino acids, such as the charge clamp residues K246 and E420 (Fig. 4A) . MD simulations of VDR wt complexed with either the natural hormone or Gemini were performed for 2 nsec, and the distance between the C ␣ -atoms of K246 and E420 was measured every 10 psec (Fig. 4B) . Within this relatively long simulation period no significant deviation from the optimal distance of 19 Å could be observed, i.e. with Limited protease digestion assays were performed by preincubating in vitro translated 35 S-labeled wild-type or mutant VDR with DMSO (as solvent control) and saturating concentrations (1 M) of 1␣,25(OH) 2 D 3 or Gemini. The assays were performed with either VDR alone or in combination with unlabeled, in vitro translated RXR and unlabeled VDRE or in combination with RXR, VDRE, and bacterially expressed GST-NCoR 1679Ϫ2453 . After digestion with trypsin, the ligand-stabilized VDR conformations c1 (active) and c3 (silent) were electrophoresed through 15% SDS-polyacrylamide gels. Representative experiments are shown. VDR conformations that are represented by c1 and c3 are schematically depicted.
both ligands helix 12 stayed in its agonistic position. This is in contrast to the results of the in vitro conformational analysis by limited protease digestion (Fig. 3) and suggests that because crystal data of apo-VDR or VDR-CoR complexes are lacking, the potential of MD simulations with VDR wt is restricted. It is likely that very long MD simulations of tens of nanoseconds are required to observe the changes between different VDR wt conformations. To avoid these restrictions, MD simulations were repeated with VDR F422A and both ligands and monitored over the rather long period of 5 nsec (Fig. 4C) . Interestingly, with Gemini the distance between K246 and E420 was found to be decreased to an average of 17.5 Å, whereas it stayed with 1␣,25(OH) 2 D 3 constant at 19 Å. This demonstrates that Gemini, but not the natural hormone, can push helix 12 into a position that prohibits interaction with CoA proteins and may favor complex formation with CoRs. When the extra side chain of Gemini is located in position 1 (blue in Fig. 4A ), it is in direct contact with H397 and L309. The side chain pushes H397 to partially fill the empty space of the missing aromatic group of the F422A mutant. At the same time, the C-terminal portion of helix 12 is rotated counterclockwise, resulting in a movement of 3 Å for the C ␣ atom of A422 and a movement of 2 Å for the C ␣ atom of L421 as compared with their positions in the x-ray structure (7), when helix 12 is in the agonistic position. However, in the absence of CoR protein the tension through Gemini's second side appears not to be strong enough to break the interaction between H397 and F422 in VDR wt . Therefore, in MD simulations, the effect can be observed only when the H397-F422 interaction is neutralized by a mutation of F422.
CONCLUSION
This study demonstrates that endocrine members of the NR superfamily, such as the VDR, can be inversely antagonized by synthetic ligands, such as Gemini. Due to its second side chain, Gemini seems to be the most flexible known VDR ligand. At endogenous CoA/CoR ratios, Gemini acts as an agonist and is at least as potent as the natural hormone. However, at CoR excess Gemini is clearly less active than 1␣,25(OH) 2 D 3 . Under the latter conditions, a subpopulation of the VDR pool may still be stabilized by Gemini in the active conformation c1, binds CoA proteins, and is responsible for the residual agonistic activity. The remaining VDR molecules also bind Gemini, but in the silent conformation c3, and do not contribute to gene activation. In contrast, as an inverse agonist, Gemini actively recruits CoR proteins to the VDR and induces superrepression. The CoR-driven shift of Gemini from agonist to inverse agonist is most pronounced when helix 12 is deleted or F422 is mutated. This suggests that the position of helix 12, which under control of its lock F422, plays an important role in determining whether Gemini acts as an agonist or an inverse agonist. On one hand, the second side chain of Gemini provides extra stability to the receptor-ligand complex, but on the other it also induces some tension to the receptor structure. Due to this yin-yang nature, Gemini is much more sensitive to changes of the CoA and CoR expression level than other VDR ligands.
Although not yet studied in detail, the CoA/CoR ratio is assumed to be an important cell-specific characteristics and can be specifically sensed by Gemini.
MATERIALS AND METHODS

Compounds
Gemini is a 21-(3-methyl-3-hydroxy-butyl) derivative of 1␣,25(OH) 2 D 3 , which carries two identical side chains at carbon 20 (22, 23) . Both VDR ligands were a gift of LEO Pharmaceuticals (Ballerup, Denmark). They were dissolved in 2-propanol; further dilutions were made either in DMSO (for in vitro experiments) or in ethanol (for cell culture experiments). The HDAC inhibitor TSA was purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA) and dissolved in ethanol.
DNA Constructs
The full-length cDNAs for human VDR (27) and human RXR␣ (36) were subcloned into the simian virus 40 promoter-driven pSG5 expression vector (Stratagene, La Jolla, CA). These constructs are also suitable for T 7 RNA polymerase-driven in vitro transcription/translation of the respective cDNAs. The DNA-binding domain of the yeast transcription factor GAL4, spanning amino acids 1-147, was fused with the cDNA of the human VDR LBD, spanning amino acids 109-427 (19) . All point mutants were generated using the QuikChange point mutagenesis kit (Stratagene) and confirmed by sequencing. The helix 12 deletion mutants of VDR and RXR (VDR ⌬H12 and RXR ⌬H12 ) were generated by introducing a stop codon at positions 413 and 444, respectively. The full-length cDNA of mouse NCoR (37) was subcloned into the cytomegalovirus promoter-driven CMX expression vector pCMX. The luciferase reporter gene was driven by one copy of the complex VDRE from the human osteocalcin gene promoter (27) , four copies of the rat ANF gene promoter (38) , or three copies of a GAL4 binding site fused to the tk promoter. A cDNA fragment of mouse NCoR (spanning amino acids 1679-2453) was subcloned into the GST fusion vector pGEX (AmershamPharmacia, Uppsala, Sweden) and a slightly larger cDNA fragment (spanning amino acids 1552-2453) was fused with the activation domain of VP16 (39) .
Transfection and Luciferase Reporter Gene Assay
MCF-7 human breast cancer cells were seeded into six-well plates (10 5 cells/ml) and grown overnight in phenol red-free DMEM supplemented with 5% charcoal-treated fetal bovine serum. For regular reporter gene assays, liposomes were formed by incubating each 1 g of osteocalcin or ANF VDREdriven reporter plasmid, pSG5-based receptor expression vectors for VDR and RXR, and pCMX-based expression vector for NCoR (as indicated) with 10 g N- [1] [2] propyl]-N,N,N-trimethylammonium methylsulfate (Roth, Karlsruhe, Germany) for 15 min at room temperature in a total volume of 100 l. After dilution with 900 l phenol red-free DMEM, the liposomes were added to the cells. Phenol redfree DMEM supplemented with 15% charcoal-treated fetal bovine serum (500 l) was added 4 h after transfection. At this time, VDR ligands or TSA were also added. For mammalian two-hybrid assays the same cells and the same transfection and stimulation procedure were applied, but different reporter and expression plasmids were used. These were a luciferase reporter gene plasmid driven by three copies of a GAL4 binding site and expression vectors for wild-type and mutant GAL4-VDR and VP16-NCoR fusion proteins. For both types of assays the cells were lysed 16 h after onset of stimulation using the reporter gene lysis buffer (Roche Diagnostics, Mannheim, Germany) and the constant-light signal luciferase reporter gene assay was performed as recommended by the supplier (Canberra-Packard, Groningen, The Netherlands). The luciferase activities were normalized with respect to protein concentration and relative activities were calculated.
In Vitro Protein Translation and Bacterial Fusion Protein Overexpression
In vitro translated VDR and RXR proteins were generated by transcribing their respective cDNA expression vector with T 7 RNA polymerase and translating these RNAs in vitro using rabbit reticulocyte lysate as recommended by the supplier (Promega Corp., Madison, WI). 35 S-labeled VDR was generated by translation in the presence of [ 35 S]methionine. Bacterial overexpression of GST-NCoR 1679Ϫ2453 was facilitated in the Escherichia coli BL21(DE3)pLysS strain (Stratagene) by induction with isopropyl-␤-D-thio-galactopyranoside (0.25 mM) for 5 h at 25 C.
GST Pull-Down Assay
The GST pull-down assay was performed with 40 l of a 50% Sepharose bead slurry of GST-NCoR 1679Ϫ2453 (preblocked with 1 g/l BSA) and 20 ng of in vitro translated, 35 S-labeled VDR (wild type or mutant) in the presence of indicated ligands. VDR proteins were incubated in immunoprecipitation buffer [20 mM HEPES (pH 7.9), 200 mM KCl, 1 mM EDTA, 4 mM MgCl 2 , 1 mM dithiothretiol, 0.1% Nonidet P-40, and 10% glycerol] for 20 min at 30 C. In vitro translated proteins that were not bound to GST-fusion proteins were washed away with immunoprecipitation buffer. GST-fusion protein-bound 35 S-labeled VDR proteins were resolved by electrophoresis through 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels and quantified on a Fuji FLA3000 reader (Tokyo, Japan) using Image Gauge software (Fuji).
Limited Protease Digestion Assay
In vitro translated, 35 S-labeled VDR protein (2 l), nonlabeled RXR (2 l), nonlabeled NCoR protein (1 l), or respective amounts of nonprogrammed reticulocyte lysate and 1 ng of unlabeled VDRE (as indicated) were incubated with ligand for 15 min at room temperature in 20 l binding buffer [10 mM HEPES (pH 7.9), 1 mM dithiothretiol, 0.2 g/l poly(dI-C), and 5% glycerol]. The buffer was adjusted to 150 mM of monovalent cations by addition of KCl. Trypsin (Promega Corp., final concentration, 8.3 ng/l) was then added, and the mixtures were further incubated for 15 min at room temperature. The digestion reactions were stopped by adding 25 l protein gel loading buffer [0.25 M Tris (pH 6.8), 20% glycerol, 5% mercaptoethanol, 2% SDS, 0.025% bromophenol blue]. The samples were denatured at 85 C for 3 min and electrophoresed through 15% SDS-polyacrylamide gels. The gels were dried, exposed to a Fuji MP2040S imager screen, and monitored on a Fuji FLA3000 reader.
MD Simulations
The initial coordinates for the MD simulations were obtained from the x-ray crystal structure of the 1␣,25(OH) 2 D 3 -VDR-LBD complex (Brookhaven Protein Data Bank code 1DB1) determined to 1.8 Å resolution (7) . The missing amino acid residues of the x-ray structure (residues 118, 119, 375-377, and 424-427) were built using the Quanta98 molecular modeling package (Molecular Simulations, Inc., San Diego, CA). The four residues missing from the C terminus (424-427) were built in an ␣-helical conformation ( ϭ Ϫ57°, ϭ Ϫ47°). The F422A mutant was generated from the wild-type VDR by placing the C ␤ of alanine to the position it has in phenylalanine. Crystallographic water molecules were included in simulation systems neutralized by placing four Na ϩ ions in the positions of largest electrostatic potential as determined by the program CION of the AMBER6.0 simulation package (University of California, San Francisco, CA). Gemini was docked to the ligand-binding pocket of the LBD using the locally enhanced sampling method, which is a mean-field technique providing ability to focus on the interesting part of the system (40) . In practice, multiple copies are employed on the part of the system where conformational sampling may be critical, and the rest of the system is treated as a single structure. For the locally enhanced sampling calculations, the protein-ligand complexes were solvated by adding a sphere of TIP3P water molecules with a 25 Å radius from the mass center of the ligand. This resulted in 764 water molecules for the complexes. Only residues having atoms within 12 Å from the atoms of the ligand were allowed to move. The water molecules of the complex were first energy minimized for 2000 steps, heated to 300 K in 5 psec, and equilibrated by 30 psec at a constant temperature of 300 K. After that, the moving part of the protein-ligand complex was minimized for 2000 steps, the temperature of the system was increased to 300 K in 5 psec and equilibrated for 75 psec using a time step of 2 fsec. The system was then heated to 400 K in 5 psec and equilibrated for 40 psec using a time step of 1 fsec and applying harmonic positional restraint of 2.0 kcal/mol. After that, the positional restraints were removed, velocities of the atoms were assigned to correspond to 340 K, and the system was cooled from 340 to 0 K in 160 psec.
For periodic box simulations, the LBD-ligand complexes were solvated by 10,778 TIP3P water molecules in a periodic box of 69ϫ61ϫ87 Å. The minimization and equilibration of water molecules were done as in the water cap simulations. Then the whole system was again energy minimized for 2000 steps, heated to 300 K in 5 psec and equilibrated by 300 psec at 300 K and pressure of 101.325 Pa. After that, 2-and 5-nsec production simulations were started. Bonds involving hydrogen atoms were constrained to their equilibrium lengths using the SHAKE algorithm. The time step of 1.5 fsec was used in periodic box simulations. The electrostatics was treated using the particlemesh Ewald method, and continuum model correction was applied for energy and pressure. The center of mass velocity was removed each 75 psec. All the simulations were done using the AMBER6 program and the force field described by Cornell et al. (41) .
